Stocks and InvestingStocks and Investing
Fri, March 15, 2019
Thu, March 14, 2019
Wed, March 13, 2019
Tue, March 12, 2019
Mon, March 11, 2019
Fri, March 8, 2019
Thu, March 7, 2019
Wed, March 6, 2019
Tue, March 5, 2019
Mon, March 4, 2019
Fri, March 1, 2019
Thu, February 28, 2019

Christopher Marai Maintained (SRPT) at Strong Buy with Increased Target to $230 on, Feb 28th, 2019


Published on 2024-10-26 12:22:54 - WOPRAI, Christopher Marai
  Print publication without navigation


Christopher Marai of Nomura, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $205 to $230 on, Feb 28th, 2019.

Christopher has made no other calls on SRPT in the last 4 months.



There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Christopher's Rating of Hold.



This is the rating of the analyst that currently disagrees with Christopher


  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $188 on, Tuesday, November 6th, 2018